Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10901642 | 0.86 | ABAT (0.32) | — | |
| SCHEMBL15583842 | 0.78 | GABRR1 (0.31) | GABRR1 | |
| SCHEMBL18929916 | 0.76 | GABRR1 (0.31) | GABRR1 | |
| SCHEMBL18857460 | 0.76 | GABRR1 (0.31) | GABRR1 | |
| SCHEMBL14839141 | 0.73 | — | — | |
| SCHEMBL15827389 | 0.73 | — | — | |
| SCHEMBL15219438 | 0.72 | — | — | |
| SCHEMBL1354859 | 0.69 | ABAT (0.31) | — | |
| SCHEMBL4794294 | 0.69 | L3MBTL1 (0.35) | — | |
| SCHEMBL23955957 | 0.68 | CHRNB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060257852-A1 | Severe acute respiratory syndrome coronavirus | CHIRON CORPORATION (US) | 2006-11-16 | — | — | US | claimed |
| EP-1618127-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | claimed |
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-0635485-A1 | TETRAHYDROPHTHALAMIDE DERIVATIVE, INTERMEDIATE FOR PRODUCING THE SAME, PRODUCTION OF BOTH, AND HERBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0251507-A2 | Carbonamide modified thermoplastic elastomer-polyoxazoline molding compositions | ARCO Chemical Technology, L.P. (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060257852-A1 | Severe acute respiratory syndrome coronavirus | SARS1, ACE2, ACE | GABRR1 2746/4885 |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | ICOS, CD14, LCP2 | GABRR1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.